US 7,601,351 B1
	Antibodies against protective antigen
Craig A. Rosen, Laytonsville, Md. (US); Michael W. Laird, Germantown, Md. (US); and Reiner L. Gentz, Belo Horizonte-Mg (Brazil)
Assigned to Human Genome Sciences, Inc., Rockville, Md. (US)
Filed on Jun. 25, 2003, as Appl. No. 10/602,727.
Claims priority of provisional application 60/391162, filed on Jun. 26, 2002.
Claims priority of provisional application 60/406339, filed on Aug. 28, 2002.
Claims priority of provisional application 60/417305, filed on Oct. 10, 2002.
Claims priority of provisional application 60/426360, filed on Nov. 15, 2002.
Claims priority of provisional application 60/434807, filed on Dec. 20, 2002.
Claims priority of provisional application 60/438004, filed on Jan. 06, 2003.
Claims priority of provisional application 60/443858, filed on Jan. 31, 2003.
Claims priority of provisional application 60/443781, filed on Jan. 31, 2003.
Claims priority of provisional application 60/454613, filed on Mar. 17, 2003.
Claims priority of provisional application 60/468651, filed on May 08, 2003.
Int. Cl. A61K 39/395 (2006.01); A61K 39/40 (2006.01)

U.S. Cl. 424—139.1  [424/164.1; 530/387.1; 530/387.9; 530/388.1; 530/388.15; 530/388.4; 530/389.1; 530/389.5; 530/391.3]

69 Claims

1. An isolated antibody or fragment thereof comprising the amino acid sequences of the VHCDR1 domain (residues 26-35 of SEQ ID NO:53), the VHCDR2 domain (residues 50-66 of SEQ ID NO:53), the VHCDR3 domain (residues 99-106 of SEQ ID NO:53), the VLCDR1 domain (residues 156-168 of SEQ ID NO:3), the VLCDR2 domain (residues 184-190 of SEQ ID NO:53), and the VLCDR3 domain (residues 223-233 of SEQ ID NO:53), of the scFv of SEQ ID NO:53, wherein said antibody or fragment thereof specifically binds protective antigen (PA).